NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

A U.S. judge denied compounding pharmacies' request to produce copies of Novo Nordisk's Ozempic and Wegovy, enforcing an FDA deadline for larger facilities to exit by May 22, 2025.

In January 2025, Novo Nordisk released data from an early-stage drug trial of a dual-action obesity medication, showing that users lost an average of up to 22% of their body weight over 36 weeks.

DBS noted structural issues at Novo Nordisk, highlighting its heavy reliance on obesity care, which poses risks from supply constraints on GLP-1 products and may limit Wegovy's growth.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.